← Human Trials & Peer-Reviewed Studies
Efficacy of Once Weekly Semaglutide in Patients With Type 2 Diabetes: a Non Randomized Clinical Trial
Plain-language guide to NCT07732218: phase 4 interventional trial of Semaglutide, 95 participants. Who took part, design and what was measured.
Key Facts
- Registry ID
- NCT07732218
- Phase
- phase 4
- Status
- completed
- Start
- 2022-07-04
- Completion (planned or actual)
- 2023-03-30
- Participants
- 95 (actual)
- Design
- na, open label (everyone knows who gets what), treatment
- Conditions studied
- Type 2 Diabetes
- Results posted
- not yet
What This Study Did, in Plain Language
What Was Tested
The trial (phase 4) is built around Semaglutide.
It had 1 arm (groups): Once-weekly Semaglutide (experimental).
The registry classes the interventions as drug.
More on the Plan
The study was conducted at two diabetes care centers in Peshawar, Pakistan, between July 2022 and March 2023.
Eligible participants received subcutaneous semaglutide once weekly for a total treatment period of 16 weeks.
Participants who were taking dipeptidyl peptidase-4 inhibitors discontinued those medications before starting semaglutide.
Other background glucose-lowering medications, including metformin, sodium-glucose cotransporter-2 inhibitors, sulfonylureas, and basal insulin, were continued at the discretion of the treating physician unless clinical adjustment was required.
Who Took Part
The registry lists 95 actual participants took part.
It was open to people of any sex aged from 18 years with no upper age limit.
Healthy volunteers were not accepted; participants needed the condition being studied.
How the Study Was Run
The set-up was single-group and open-label.
Being open-label, the Semaglutide study did not mask who received what.
Everyone received the same intervention, so there was no separate comparison group inside the trial.
It started in 2022-07-04 with completion listed for 2023-03-30.
It ran at 1 site in Pakistan.
Its stated primary purpose is treatment.
What Was Measured
Primary outcome: Change in Glycated hemoglobin (time frame: baseline and 16 week). Changes in Glycated Hemoglobin (time frame: Baseline and week 16).
It also tracked 4 secondary outcomes, for example Changes in body weight, Changes in BMI, Changes in fasting Blood Glucose and Change in random blood glucose.
What This Means in Plain Language
Put simply, this is a phase 4 trial of Semaglutide in 95 people.
The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.
More context: the Semaglutide compound page, all human trials.
Our Notes on the Compound
Semaglutide: The active ingredient in several prescription GLP-1 receptor agonist medicines (Ozempic, Wegovy, oral tablets).
Related Pages
Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.